{{header
 | author     = Steve Stivers
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2014
 | month      = 06
 | day        = 19
 | notes      = ''{{USBill|113|H.R.|4918}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 2
 | title      = Speeding Access to Already Approved Pharmaceuticals Act of 2014 ( H.R. 4918; 113th Congress)
 | bill       = 4918
 | billtype   = hr
 | purpose    = To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.
 | wikipedia  =
}}
      
{{Center|113th CONGRESS}}

 
{{Center|2d Session}}

 
{{Center|H. R. 4918}}

 
{{Center|IN THE HOUSE OF REPRESENTATIVES}}

  
{{Center|June 19, 2014}}

 
{{Center| 
[[w:Steve Stivers|Mr. Stivers]](for himself and
[[w:Tim Ryan (politician)|Mr. Ryan of Ohio]]) introduced the following bill; which was referred to the [[w:United States House Committee on Energy and Commerce|Committee on Energy and Commerce]] }}

  
{{Center|A BILL}}

 To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.   

=Section 1. Short title=

This Act may be cited as the“   Speeding Access to Already Approved Pharmaceuticals Act of 2014   ”. 

=Sec. 2. Expedited review of EU-approved pharmaceuticals=



==(a) In general– ==

   Section 506 of the Federal Food, Drug, and Cosmetic Act ( [http://www.law.cornell.edu/uscode/text/21/356 21 U.S.C. 356] )is amended by adding at the end the following:

<blockquote> 

===(g) EU-Approved pharmaceuticals– ===



====(1) Expedited review– ====

Beginning not later than 90 days after a new pharmaceutical is approved for marketing in the European Union, the [[w:Department of Health and Human Services|Secretary]]shall, at the request of the sponsor of the pharmaceutical, facilitate the development and expedite the review of such new pharmaceutical under section 505 or 515 of this Act or section 351 of the Public Health Service Act , as appropriate.

====(2) Definition– ====

In this subsection, the term pharmaceutical means a drug (including a biological product) or a device. . 
</blockquote>


==(b) Technical correction– ==

   Subsection (f) (relating to awareness efforts) of section 506 of the Federal Food, Drug, and Cosmetic Act ( [http://www.law.cornell.edu/uscode/text/21/356 21 U.S.C. 356] )is hereby moved so as to follow subsection (e) (relating to construction) of such section 506 .  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
